Benzinga · Jul 29, 2026
OS Therapies Terminates At Market Issuance Sales Agreement On July 23; Co. Announces Termination Of Sales Agreement Effective July 28
- Sec Filing
OS
NYSE · OSTX
OS Therapies Incorporated
Healthcare · Biotechnology
$1.60
Down-$0.01 (-0.62%)
Updated Aug 14, 2026, 4:11 AM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 71.66M
- P/E ratio
- -0.01
- Dividend yield
- 0.00%
- 52-week range
- $1.15 – $2.57
- Volume
- 573.39K
- Avg. volume
- 342.06K
Price performance
OSTX price history
1M range · 0 trading sessions · Daily adjusted prices
OSTX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest OSTX news
The latest Smart Investors Daily articles mentioning OSTX.
Stock researchCompany · Overview
OSTX research
Overview
Company profile and research snapshot.
Company profile
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the need for new treatments in cancers of the bone in children and young adults.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $13.01
- Implied upside
- —
- Analysts
- 10
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 9, 2026 | Roth Capital | Buy | — |
| May 19, 2026 | Lake Street | Buy | — |
| Apr 30, 2026 | D. Boral Capital | Buy | — |
| Apr 8, 2026 | D. Boral Capital | Buy | — |
| Mar 27, 2026 | D. Boral Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Jul 9, 2026
Roth Capital Initiates Coverage On OS Therapies with Buy Rating, Announces Price Target of $7
Roth Capital analyst Adam Walsh initiates coverage on OS Therapies (AMEX:OSTX) with a Buy rating and announces Price Target of $7.
Benzinga · Jul 8, 2026
OS Therapies Accepts New FDA Meeting Request For Review Of Pharmacodynamic Response Biomarker Data
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has accepted a new Meeting Request from
Benzinga · Jul 6, 2026
OS Therapies Expects Phase 3 Study For The OST-HER2 Metastatic Osteosarcoma Program To Begin Near End Of Q3 2026
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today provides a third quarter 2026 corporate outlook. The
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
